Prelude Therapeutics annual return on assets (roa)
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Return on Assets (ROA) Growth & History (PRLD)
Prelude Therapeutics's return on assets (roa) was −62.81% for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −62.81% | −6.68 pp |
| 2024 | 2024-12-31 | −56.12% | −7.21 pp |
| 2023 | 2023-12-31 | −48.91% | −4.99 pp |
| 2022 | 2022-12-31 | −43.93% | −1.67 pp |
| 2021 | 2021-12-31 | −42.25% | +4.13 pp |
| 2020 | 2020-12-31 | −46.39% | — |
Prelude Therapeutics quarterly return on assets (roa)
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −39.76% | +33.54 pp |
| Q1 2026 | 2026-03-31 | −59.64% | +6.19 pp |
| Q4 2025 | 2025-12-31 | −62.81% | −6.68 pp |
| Q3 2025 | 2025-09-30 | −76.56% | −18.85 pp |
| Q2 2025 | 2025-06-30 | −73.30% | −21.86 pp |
| Q1 2025 | 2025-03-31 | −65.83% | −9.46 pp |
| Q4 2024 | 2024-12-31 | −56.12% | −7.21 pp |
| Q3 2024 | 2024-09-30 | −57.72% | −10.84 pp |
| Q2 2024 | 2024-06-30 | −51.44% | −8.17 pp |
| Q1 2024 | 2024-03-31 | −56.37% | −8.90 pp |
| Q4 2023 | 2023-12-31 | −48.91% | −4.99 pp |
| Q3 2023 | 2023-09-30 | −46.88% | −5.16 pp |
| Q2 2023 | 2023-06-30 | −43.27% | −3.71 pp |
| Q1 2023 | 2023-03-31 | −47.47% | −10.62 pp |
| Q4 2022 | 2022-12-31 | −43.93% | −1.67 pp |
| Q3 2022 | 2022-09-30 | −41.72% | −7.35 pp |
| Q2 2022 | 2022-06-30 | −39.55% | +5.77 pp |
| Q1 2022 | 2022-03-31 | −36.85% | — |
| Q4 2021 | 2021-12-31 | −42.25% | — |
| Q3 2021 | 2021-09-30 | −34.37% | — |
| Q2 2021 | 2021-06-30 | −45.32% | — |
Prelude Therapeutics return on assets (roa) trends
Over the last five fiscal years, Prelude Therapeutics's return on assets (roa) decreased from −46.39% to −62.81%, a change of −16.42 percentage points. The latest reported quarter, Q2 2026, shows −39.76%.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...